about
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytesImmunophenotypic analysis of Waldenstrom's macroglobulinemiaImmunophenotypical detection of minimal residual disease in acute leukemia.Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML).Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients.Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response.Expression of APO2.7, bcl-2 and bax apoptosis-associated proteins in CD34- bone marrow cell compartments from patients with myelodysplastic syndromes.High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics.Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance.CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potentialClinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patientsHigh-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myelomaMultiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005<65y TrialsCompetition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myelomaThe Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma CellsBortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple mThe persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patientsPrognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose TherapyHematological, immunophenotypic, and cytogenetic characteristics of acute myeloblastic leukemia with trisomy 11Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratificationThe clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosisDNA aneuploidy in acute myeloblastic leukemia is associated with a high expression of lymphoid markersLymphoid subsets in acute myeloid leukemias: increased number of cells with NK phenotype and normal T-cell distributionCharacterization of aberrant phenotypes in acute myeloblastic leukemiaAn abnormal CD34+ myeloid/CD34+ lymphoid ratio at the end of chemotherapy predicts relapse in patients with acute myeloid leukemiaMinimal residual disease monitoring by flow cytometryComparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myelomaPhase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemiaRisk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cellsMultiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma
P50
Q24604581-7A9EE589-05FD-4DB3-B94F-769BA4236F6CQ28201709-B274E3EC-9B3F-4779-A7BF-9F899E08E491Q33816575-E9CA33F9-AAA2-4586-926C-01C24D3BA708Q34623072-026FB010-06F0-466C-969A-7BD69B63B4DBQ36498366-2DF4849B-F3BF-414F-A307-4A4A46B6A75CQ37406818-F48EB58A-90A2-44B0-A673-EFCD1621F4FDQ39590174-A6597CB0-300E-4D74-9898-6CF14CC5D6BDQ47677785-C93D7BB6-C235-4D16-AEE7-7A0EE28F68B1Q47758619-DCF796AF-DBAF-4525-A5B5-817403D8E1B5Q47996009-E9C07EDB-7E3B-413B-98DA-CF5234BE6FBAQ51533765-49A2F0AD-88F9-4CAD-9A87-1CF5609C50ACQ53878426-EE32DC4A-156C-47AE-9A17-79FFC8676936Q60203335-DB93C752-42C7-46AD-87B6-A54D7FD593E8Q60203477-6E822114-C99D-44E9-98C7-D4F8B957EE21Q60203492-5017E726-5994-40DF-B167-F9BFFBE0E131Q60203544-26E1D8BE-D4BD-4F55-84AB-367EDA0C6AEBQ60203595-B7178C5A-2CD9-4F11-B996-3E02D42928CFQ60203614-0718A9D8-1113-4306-A31C-2B0AE7CE1FF5Q60203634-00660CBD-A436-44EC-808B-A4480F304D69Q60203704-2DFF88B1-59C7-407B-BAAC-BDF9355D21B1Q60203750-F3FD1BB2-0479-4951-A1A8-0F03A675D991Q60203901-45F248C2-69AA-4F51-B43D-3C6808D81C6AQ60204043-1252804A-5278-4BE5-95CD-C8C8821FDD79Q60679310-BE3D2219-BB13-4733-B5E1-BC37A3BF2859Q71811565-8ACEDFDF-234D-4C42-931C-A6BFC98AD502Q72105922-F93DDDC3-5C47-48A9-AC13-E7C552A83981Q72233543-E3776773-82AF-48B8-91AD-4758F68636AAQ77738098-1FB3B7F5-7F97-40F1-BB4C-D4387A8448DDQ79236551-12799F06-9C53-4D87-BFED-3919C3776C12Q83608464-7ED3877B-447C-4EC9-874D-6206D80D7147Q83967551-7B1CFBCE-4D1B-4FE2-A22C-348A91924881Q84702938-6C6B75AC-DC7A-4834-96F8-00E55C7F7D0AQ87982213-038DFDF3-63B8-4FE7-AB70-6ADFEC888B56
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
María-Belén Vidriales
@ast
María-Belén Vidriales
@en
María-Belén Vidriales
@es
María-Belén Vidriales
@nl
María-Belén Vidriales
@sl
type
label
María-Belén Vidriales
@ast
María-Belén Vidriales
@en
María-Belén Vidriales
@es
María-Belén Vidriales
@nl
María-Belén Vidriales
@sl
prefLabel
María-Belén Vidriales
@ast
María-Belén Vidriales
@en
María-Belén Vidriales
@es
María-Belén Vidriales
@nl
María-Belén Vidriales
@sl
P106
P1153
6701445648
P21
P31
P496
0000-0001-5049-3673